Apoptotic cell signaling in cancer progression and therapy.
暂无分享,去创建一个
[1] Sven Diederichs,et al. The hallmarks of cancer , 2012, RNA biology.
[2] C. Croce,et al. microRNAs: Master regulators as potential therapeutics in cancer. , 2011, Annual review of pharmacology and toxicology.
[3] J. Martinez-Climent,et al. Reversion of epigenetically mediated BIM silencing overcomes chemoresistance in Burkitt lymphoma. , 2010, Blood.
[4] D. Altieri. Survivin and IAP proteins in cell-death mechanisms. , 2010, The Biochemical journal.
[5] H. Kashkar. X-linked Inhibitor of Apoptosis: A Chemoresistance Factor or a Hollow Promise , 2010, Clinical Cancer Research.
[6] Pascal Meier,et al. IAPs: from caspase inhibitors to modulators of NF-κB, inflammation and cancer , 2010, Nature Reviews Cancer.
[7] C. Pepper,et al. The role of Bcl-2 family proteins in chronic lymphocytic leukaemia. , 2010, Leukemia research.
[8] C. Boland,et al. Mutations in TGFbeta-RII and BAX mediate tumor progression in the later stages of colorectal cancer with microsatellite instability , 2010, BMC Cancer.
[9] Mallika Singh,et al. Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models , 2010, Nature Biotechnology.
[10] Subbaya Subramanian,et al. MicroRNAs as gatekeepers of apoptosis , 2010, Journal of cellular physiology.
[11] C. Croce,et al. MicroRNAs as regulators of death receptors signaling , 2010, Cell Death and Differentiation.
[12] J. Houghton,et al. Inhibition of NF-κB Signaling by Quinacrine Is Cytotoxic to Human Colon Carcinoma Cell Lines and Is Synergistic in Combination with Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) or Oxaliplatin , 2010, The Journal of Biological Chemistry.
[13] C. Meijer,et al. Molecular targeted therapies for diffuse large B‐cell lymphoma based on apoptosis profiles , 2010, The Journal of pathology.
[14] M. Baker. RNA interference: Homing in on delivery , 2010, Nature.
[15] Mark E. Davis,et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles , 2010, Nature.
[16] Jian Yu,et al. Mitochondrial signaling in cell death via the Bcl-2 family , 2010, Cancer biology & therapy.
[17] Raimund Mannhold,et al. IAP antagonists: promising candidates for cancer therapy. , 2010, Drug discovery today.
[18] T. Halazonetis,et al. Genomic instability — an evolving hallmark of cancer , 2010, Nature Reviews Molecular Cell Biology.
[19] S. Fulda. Evasion of Apoptosis as a Cellular Stress Response in Cancer , 2010, International journal of cell biology.
[20] G. Brumatti,et al. Crossing paths: interactions between the cell death machinery and growth factor survival signals , 2010, Cellular and Molecular Life Sciences.
[21] D. Green,et al. The BCL-2 family reunion. , 2010, Molecular cell.
[22] L. Blum,et al. Active Fragments from Pro- and Antiapoptotic BCL-2 Proteins Have Distinct Membrane Behavior Reflecting Their Functional Divergence , 2010, PloS one.
[23] C. Croce,et al. miR-15a and miR-16-1 in cancer: discovery, function and future perspectives , 2010, Cell Death and Differentiation.
[24] S. Canevari,et al. Cellular FLICE-inhibitory protein (c-FLIP) signalling: a key regulator of receptor-mediated apoptosis in physiologic context and in cancer. , 2010, The international journal of biochemistry & cell biology.
[25] H. Hermeking. The miR-34 family in cancer and apoptosis , 2010, Cell Death and Differentiation.
[26] W. Fairbrother,et al. Small-molecule pan-IAP antagonists: a patent review , 2010, Expert opinion on therapeutic patents.
[27] L. Languino,et al. IAP regulation of metastasis. , 2010, Cancer cell.
[28] C. Croce,et al. MicroRNA 29b functions in acute myeloid leukemia. , 2009, Blood.
[29] Liu Hao,et al. Expression of X‐linked inhibitor of apoptosis protein in human colorectal cancer and its correlation with prognosis , 2009, Journal of surgical oncology.
[30] H. Steinhoff,et al. Molecular Details of Bax Activation, Oligomerization, and Membrane Insertion* , 2009, The Journal of Biological Chemistry.
[31] P. Meier,et al. A tangled web of ubiquitin chains: breaking news in TNF-R1 signaling. , 2009, Molecular cell.
[32] J. Hsieh,et al. Stepwise activation of BAX and BAK by tBID, BIM, and PUMA initiates mitochondrial apoptosis. , 2009, Molecular cell.
[33] S. Bruno,et al. BH3‐only proteins: The death‐puppeteer's wires , 2009, Cytometry. Part A : the journal of the International Society for Analytical Cytology.
[34] T. Hofmann,et al. Apoptosis and autophagy: Regulation of apoptosis by DNA damage signalling – roles of p53, p73 and HIPK2 , 2009, The FEBS journal.
[35] M. Duffy,et al. Survivin: a new target for anti-cancer therapy. , 2009, Cancer treatment reviews.
[36] A. Chanan-Khan,et al. Targeting the Bcl-2 , 2009, Current opinion in oncology.
[37] J. Yun,et al. Effects of MicroRNA‐29 on apoptosis, tumorigenicity, and prognosis of hepatocellular carcinoma , 2009, Hepatology.
[38] C. Croce. Causes and consequences of microRNA dysregulation in cancer , 2009, Nature Reviews Genetics.
[39] M. Kurokawa,et al. Caspases and Kinases in a Death Grip , 2009, Cell.
[40] Min Zhang,et al. MicroRNA miR-34 Inhibits Human Pancreatic Cancer Tumor-Initiating Cells , 2009, PloS one.
[41] S. Fulda. Caspase-8 in cancer biology and therapy. , 2009, Cancer letters.
[42] G. Dewson,et al. Mechanisms by which Bak and Bax permeabilise mitochondria during apoptosis , 2009, Journal of Cell Science.
[43] Erinna F. Lee,et al. The role of BH3-only protein Bim extends beyond inhibiting Bcl-2–like prosurvival proteins , 2009, The Journal of cell biology.
[44] M. Willingham,et al. Expression of the Bcl-2 Protein BAD Promotes Prostate Cancer Growth , 2009, PloS one.
[45] T. Cotter,et al. Apoptosis and cancer: the genesis of a research field , 2009, Nature Reviews Cancer.
[46] M. Aung,et al. Role of the miR‐106b‐25 microRNA cluster in hepatocellular carcinoma , 2009, Cancer science.
[47] T. Wilson,et al. Procaspase 8 overexpression in non-small-cell lung cancer promotes apoptosis induced by FLIP silencing , 2009, Cell Death and Differentiation.
[48] B. Cravatt,et al. Comparative assessment of large-scale proteomic studies of apoptotic proteolysis. , 2009, ACS chemical biology.
[49] D. Saur,et al. HDAC2 mediates therapeutic resistance of pancreatic cancer cells via the BH3-only protein NOXA , 2009, Gut.
[50] W. Filipowicz,et al. Mechanisms of miRNA-mediated post-transcriptional regulation in animal cells. , 2009, Current opinion in cell biology.
[51] G. Gores,et al. Life and death by death receptors , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[52] A. Safa,et al. RNA interference in cancer: targeting the anti-apoptotic protein c-FLIP for drug discovery. , 2009, Mini reviews in medicinal chemistry.
[53] G. Salvesen,et al. Human Caspases: Activation, Specificity, and Regulation* , 2009, The Journal of Biological Chemistry.
[54] Yigong Shi,et al. Mechanism of procaspase-8 activation by c-FLIPL , 2009, Proceedings of the National Academy of Sciences.
[55] F. Sato,et al. The miR-106b-25 polycistron, activated by genomic amplification, functions as an oncogene by suppressing p21 and Bim. , 2009, Gastroenterology.
[56] S. de Jong,et al. TRAIL receptor signalling and modulation: Are we on the right TRAIL? , 2009, Cancer treatment reviews.
[57] T. Wilson,et al. Anti-apoptotic mechanisms of drug resistance in cancer. , 2009, Current cancer drug targets.
[58] P. Gimenez-Bonafe,et al. Overcoming drug resistance by enhancing apoptosis of tumor cells. , 2009, Current cancer drug targets.
[59] D. Green,et al. Cytoplasmic functions of the tumour suppressor p53 , 2009, Nature.
[60] G. Torzilli,et al. Inhibitors of apoptosis proteins (IAPs) expression and their prognostic significance in hepatocellular carcinoma , 2009, BMC Cancer.
[61] J. Hickman,et al. Bax activation by the BH3-only protein Puma promotes cell dependence on antiapoptotic Bcl-2 family members , 2009, The Journal of cell biology.
[62] A. Letai. Puma strikes Bax , 2009, The Journal of cell biology.
[63] Mark E. Davis. The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. , 2009, Molecular pharmaceutics.
[64] L. Donehower,et al. MMP13, Birc2 (cIAP1), and Birc3 (cIAP2), amplified on chromosome 9, collaborate with p53 deficiency in mouse osteosarcoma progression. , 2009, Cancer research.
[65] S. Fulda. Inhibitor of apoptosis proteins in hematological malignancies , 2009, Leukemia.
[66] G. Bao,et al. Expression and biological significance of c-FLIP in human hepatocellular carcinomas , 2009, Journal of experimental & clinical cancer research : CR.
[67] C. Reynolds,et al. Bcl-2 Inhibitors: Targeting Mitochondrial Apoptotic Pathways in Cancer Therapy , 2009, Clinical Cancer Research.
[68] A. Letai,et al. Control of mitochondrial apoptosis by the Bcl-2 family , 2009, Journal of Cell Science.
[69] S. Fulda. Tumor resistance to apoptosis , 2009, International journal of cancer.
[70] Daniel G. Anderson,et al. Knocking down barriers: advances in siRNA delivery , 2009, Nature Reviews Drug Discovery.
[71] D. Andrews,et al. Membrane Binding by tBid Initiates an Ordered Series of Events Culminating in Membrane Permeabilization by Bax , 2008, Cell.
[72] P. Bouillet,et al. BH3-only proteins and their roles in programmed cell death , 2008, Oncogene.
[73] D. Andrews,et al. Bid: a Bax-like BH3 protein , 2008, Oncogene.
[74] C. Scott,et al. In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas , 2008, Proceedings of the National Academy of Sciences.
[75] Hiroyuki Tagawa,et al. MicroRNA-17-92 down-regulates expression of distinct targets in different B-cell lymphoma subtypes. , 2008, Blood.
[76] V. Duronio. The life of a cell: apoptosis regulation by the PI3K/PKB pathway. , 2008, The Biochemical journal.
[77] R. Hofer-Warbinek,et al. XIAP regulates bi-phasic NF-kappaB induction involving physical interaction and ubiquitination of MEKK2. , 2008, Cellular signalling.
[78] John Calvin Reed,et al. Bcl-2 family proteins and cancer , 2008, Oncogene.
[79] Junying Yuan,et al. Caspases in apoptosis and beyond , 2008, Oncogene.
[80] S. Baird,et al. IAP-targeted therapies for cancer , 2008, Oncogene.
[81] Yigong Shi,et al. FLIP and the death effector domain family , 2008, Oncogene.
[82] Min Zhang,et al. Restoration of tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres , 2008, BMC Cancer.
[83] N. Tjandra,et al. BAX Activation is Initiated at a Novel Interaction Site , 2008, Nature.
[84] K. Pienta,et al. Natural BH3 mimetic (-)-gossypol chemosensitizes human prostate cancer via Bcl-xL inhibition accompanied by increase of Puma and Noxa , 2008, Molecular Cancer Therapeutics.
[85] R. Khosravi‐Far,et al. Dysregulation of apoptotic signaling in cancer: Molecular mechanisms and therapeutic opportunities , 2008, Journal of cellular biochemistry.
[86] D. Andrews,et al. Bcl-XL Inhibits Membrane Permeabilization by Competing with Bax , 2008, PLoS biology.
[87] Simone Fulda,et al. Targeting inhibitor of apoptosis proteins (IAPs) for cancer therapy. , 2008, Anti-cancer agents in medicinal chemistry.
[88] A. Donfrancesco,et al. Antagomir-17-5p Abolishes the Growth of Therapy-Resistant Neuroblastoma through p21 and BIM , 2008, PloS one.
[89] Xiaodong Wang,et al. TNF-α Induces Two Distinct Caspase-8 Activation Pathways , 2008, Cell.
[90] P. Colman,et al. To trigger apoptosis, Bak exposes its BH3 domain and homodimerizes via BH3:groove interactions. , 2008, Molecular cell.
[91] F. Kruyt. TRAIL and cancer therapy. , 2008, Cancer letters.
[92] Sharon J. Diskin,et al. A Functional Screen Identifies miR-34a as a Candidate Neuroblastoma Tumor Suppressor Gene , 2008, Molecular Cancer Research.
[93] D. Radisky,et al. Mechanisms of Disease: epithelial–mesenchymal transition—does cellular plasticity fuel neoplastic progression? , 2008, Nature Clinical Practice Oncology.
[94] John Calvin Reed. Bcl-2-family proteins and hematologic malignancies: history and future prospects. , 2008, Blood.
[95] C. Croce,et al. MiR-15a and miR-16-1 cluster functions in human leukemia , 2008, Proceedings of the National Academy of Sciences.
[96] H. Mertsching,et al. Human skin equivalent as an alternative to animal testing , 2008, GMS Krankenhaushygiene interdisziplinar.
[97] Jiri Bartek,et al. An Oncogene-Induced DNA Damage Model for Cancer Development , 2008, Science.
[98] S. Ghosh,et al. Shared Principles in NF-κB Signaling , 2008, Cell.
[99] V. Bumbasirevic,et al. TRAIL induces proliferation of human glioma cells by c-FLIPL-mediated activation of ERK1/2 , 2008, Cellular and Molecular Life Sciences.
[100] V. Seifert,et al. Pharmacological inhibition of Bcl-2 family members reactivates TRAIL-induced apoptosis in malignant glioma , 2008, Journal of Neuro-Oncology.
[101] A. Safa,et al. Cellular FLICE-like inhibitory protein (C-FLIP): a novel target for cancer therapy. , 2008, Current cancer drug targets.
[102] N. Danial,et al. BCL-2 Family Proteins: Critical Checkpoints of Apoptotic Cell Death , 2007, Clinical Cancer Research.
[103] Xiao-yong Lei,et al. Bcl-2 small interfering RNA sensitizes cisplatin-resistant human lung adenocarcinoma A549/DDP cell to cisplatin and diallyl disulfide. , 2007, Acta biochimica et biophysica Sinica.
[104] B. Gillissen,et al. Frequent loss of expression of the pro-apoptotic protein Bim in renal cell carcinoma: evidence for contribution to apoptosis resistance , 2007, Oncogene.
[105] H. Otu,et al. c-Fos as a proapoptotic agent in TRAIL-induced apoptosis in prostate cancer cells. , 2007, Cancer research.
[106] G. Gores,et al. mir-29 regulates Mcl-1 protein expression and apoptosis , 2007, Oncogene.
[107] L. Bruhn,et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. , 2007, Cancer cell.
[108] P. Korkolopoulou,et al. c‐FLIP expression in colorectal carcinomas: association with Fas/FasL expression and prognostic implications , 2007, Histopathology.
[109] F. Khuri,et al. Lipid rafts and nonrafts mediate tumor necrosis factor related apoptosis-inducing ligand induced apoptotic and nonapoptotic signals in non small cell lung carcinoma cells. , 2007, Cancer research.
[110] D. Altieri,et al. Compartmentalized phosphorylation of IAP by protein kinase A regulates cytoprotection. , 2007, Molecular cell.
[111] Xiao-yong Lei,et al. Bcl-XL small interfering RNA sensitizes cisplatin-resistant human lung adenocarcinoma cells. , 2007, Acta biochimica et biophysica Sinica.
[112] Dimitri Semizarov,et al. Integrative Genomic Analysis of Small-Cell Lung Carcinoma Reveals Correlates of Sensitivity to Bcl-2 Antagonists and Uncovers Novel Chromosomal Gains , 2007, Molecular Cancer Research.
[113] S. Cory,et al. The Bcl-2 apoptotic switch in cancer development and therapy , 2007, Oncogene.
[114] David W. Andrews,et al. Embedded together: The life and death consequences of interaction of the Bcl-2 family with membranes , 2007, Apoptosis.
[115] Erinna F. Lee,et al. Apoptosis Initiated When BH3 Ligands Engage Multiple Bcl-2 Homologs, Not Bax or Bak , 2007, Science.
[116] S. Martin,et al. The CASBAH: a searchable database of caspase substrates , 2007, Cell Death and Differentiation.
[117] M. Bissell. Modelling molecular mechanisms of breast cancer and invasion: lessons from the normal gland. , 2007, Biochemical Society transactions.
[118] C. Castilla,et al. Bcl-xL is overexpressed in hormone-resistant prostate cancer and promotes survival of LNCaP cells via interaction with proapoptotic Bak. , 2006, Endocrinology.
[119] Mallika Singh,et al. Using Genetically Engineered Mouse Models of Cancer to Aid Drug Development: An Industry Perspective , 2006, Clinical Cancer Research.
[120] G. Salvesen,et al. Human inhibitor of apoptosis proteins: why XIAP is the black sheep of the family , 2006, EMBO reports.
[121] Zhengxin Wang,et al. Androgen receptor and prostate apoptosis response factor-4 target the c-FLIP gene to determine survival and apoptosis in the prostate gland. , 2006, Journal of molecular endocrinology.
[122] B. Dörken,et al. Loss of the tissue-specific proapoptotic BH3-only protein Nbk/Bik is a unifying feature of renal cell carcinoma , 2006, Cell Death and Differentiation.
[123] G. Salvesen,et al. The Human Anti-apoptotic Proteins cIAP1 and cIAP2 Bind but Do Not Inhibit Caspases* , 2006, Journal of Biological Chemistry.
[124] M. Reth,et al. Human T‐cell leukemia virus type‐I oncoprotein Tax inhibits Fas‐mediated apoptosis by inducing cellular FLIP through activation of NF‐κB , 2006 .
[125] M. Hinds,et al. Regulation of apoptosis: uncovering the binding determinants. , 2005, Current opinion in structural biology.
[126] Ki-Young Lee,et al. TAK1, but not TAB1 or TAB2, plays an essential role in multiple signaling pathways in vivo. , 2005, Genes & development.
[127] R A Knight,et al. Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009 , 2005, Cell Death and Differentiation.
[128] D. Newmeyer,et al. Mitochondria: pharmacological manipulation of cell death. , 2005, The Journal of clinical investigation.
[129] C. Croce,et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[130] M. Shipp,et al. Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach. , 2005, Blood.
[131] Y-j Liu,et al. Expression of cellular FLICE/caspase‐8 inhibitory protein is associated with malignant potential in endometrial carcinoma , 2005, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.
[132] Jyotika Sharma,et al. Bcl-XL Protein Levels Determine Apoptotic Index in Pancreatic Carcinoma , 2005, Pancreas.
[133] P. Krammer,et al. c-FLIPR, a New Regulator of Death Receptor-induced Apoptosis* , 2005, Journal of Biological Chemistry.
[134] J. Sabourin,et al. Role of bax mutations in apoptosis in colorectal cancers with microsatellite instability. , 2005, American journal of clinical pathology.
[135] W. Marasco,et al. Predominant Bcl-XL knockdown disables antiapoptotic mechanisms: tumor necrosis factor-related apoptosis-inducing ligand-based triple chemotherapy overcomes chemoresistance in pancreatic cancer cells in vitro. , 2005, Cancer research.
[136] B. Fang,et al. Mechanisms of resistance to TRAIL-induced apoptosis in cancer , 2005, Cancer Gene Therapy.
[137] T. Kuwana,et al. BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly. , 2005, Molecular cell.
[138] H. Tagawa,et al. Genome-wide array-based CGH for mantle cell lymphoma: identification of homozygous deletions of the proapoptotic gene BIM , 2005, Oncogene.
[139] Brian J. Smith,et al. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. , 2005, Molecular cell.
[140] W. El-Deiry,et al. Overview of cell death signaling pathways , 2005, Cancer biology & therapy.
[141] P. Isaacson,et al. Gastrointestinal lymphoma: where morphology meets molecular biology , 2005, The Journal of pathology.
[142] S. Lowe,et al. Intrinsic tumour suppression , 2004, Nature.
[143] R. Khosravi‐Far. Death receptor signals to the mitochondria , 2004, Cancer biology & therapy.
[144] Hongmei Yang,et al. Persistent c-FLIP(L) Expression Is Necessary and Sufficient to Maintain Resistance to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand–Mediated Apoptosis in Prostate Cancer , 2004, Cancer Research.
[145] D. Green,et al. The Pathophysiology of Mitochondrial Cell Death , 2004, Science.
[146] Victor E. Marquez,et al. Microarray Analysis of Epigenetic Silencing of Gene Expression in the KAS-6/1 Multiple Myeloma Cell Line , 2004, Cancer Research.
[147] S. Korsmeyer,et al. Cell Death Critical Control Points , 2004, Cell.
[148] Alexei Degterev,et al. A decade of caspases , 2003, Oncogene.
[149] Wei-Guo Zhu,et al. A comprehensive search for DNA amplification in lung cancer identifies inhibitors of apoptosis cIAP1 and cIAP2 as candidate oncogenes. , 2003, Human molecular genetics.
[150] D. Green,et al. A unified model for apical caspase activation. , 2003, Molecular cell.
[151] C. Croce,et al. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[152] S. Matsuda,et al. Bcl-xL overexpression in human hepatocellular carcinoma. , 2002, International journal of oncology.
[153] Sophie Lelièvre,et al. beta4 integrin-dependent formation of polarized three-dimensional architecture confers resistance to apoptosis in normal and malignant mammary epithelium. , 2002, Cancer cell.
[154] Xiaolu Yang,et al. c‐FLIPL is a dual function regulator for caspase‐8 activation and CD95‐mediated apoptosis , 2002, The EMBO journal.
[155] G. Kroemer. Introduction: mitochondrial control of apoptosis. , 2002, Biochimie.
[156] X. Wang. The expanding role of mitochondria in apoptosis. , 2001, Genes & development.
[157] D. Crețoiu,et al. Phagocytosis of apoptotic cells by microglia in vitro , 2001, Journal of cellular and molecular medicine.
[158] J. Inazawa,et al. Identification of cIAP1 as a candidate target gene within an amplicon at 11q22 in esophageal squamous cell carcinomas. , 2001, Cancer research.
[159] Peter Scheurich,et al. NF-κB Inducers Upregulate cFLIP, a Cycloheximide-Sensitive Inhibitor of Death Receptor Signaling , 2001, Molecular and Cellular Biology.
[160] M J Bissell,et al. Tumors are unique organs defined by abnormal signaling and context. , 2001, Seminars in cancer biology.
[161] R. Korneluk,et al. Expression and genetic analysis of XIAP-associated factor 1 (XAF1) in cancer cell lines. , 2000, Genomics.
[162] Claus Belka,et al. Caspase-8/FLICE functions as an executioner caspase in anticancer drug-induced apoptosis , 2000, Oncogene.
[163] R. Meyermann,et al. Antiapoptotic Bcl‐2 family protein expression increases with progression of oligodendroglioma , 1999, Cancer.
[164] V. Weaver,et al. Functional Culture Models to Study Mechanisms Governing Apoptosis in Normal and Malignant Mammary Epithelial Cells , 1999, Journal of Mammary Gland Biology and Neoplasia.
[165] Emad S. Alnemri,et al. Ordering the Cytochrome c–initiated Caspase Cascade: Hierarchical Activation of Caspases-2, -3, -6, -7, -8, and -10 in a Caspase-9–dependent Manner , 1999, The Journal of cell biology.
[166] Xiaodong Wang,et al. Bid, a Bcl2 Interacting Protein, Mediates Cytochrome c Release from Mitochondria in Response to Activation of Cell Surface Death Receptors , 1998, Cell.
[167] Junying Yuan,et al. Cleavage of BID by Caspase 8 Mediates the Mitochondrial Damage in the Fas Pathway of Apoptosis , 1998, Cell.
[168] M. Peter,et al. Two CD95 (APO‐1/Fas) signaling pathways , 1998, The EMBO journal.
[169] V. Weaver,et al. Structural Cues from the Tissue Microenvironment Are Essential Determinants of the Human Mammary Epithelial Cell Phenotype , 1998, Journal of Mammary Gland Biology and Neoplasia.
[170] John Calvin Reed,et al. BCL-X expression in multiple myeloma: possible indicator of chemoresistance. , 1998, Cancer research.
[171] S. Srinivasula,et al. Cytochrome c and dATP-Dependent Formation of Apaf-1/Caspase-9 Complex Initiates an Apoptotic Protease Cascade , 1997, Cell.
[172] K. Franssila,et al. BCL2 overexpression associated with chromosomal amplification in diffuse large B-cell lymphoma. , 1997, Blood.
[173] Margot Thome,et al. Inhibition of death receptor signals by cellular FLIP , 1997, Nature.
[174] J C Reed,et al. Somatic Frameshift Mutations in the BAX Gene in Colon Cancers of the Microsatellite Mutator Phenotype , 1997, Science.
[175] C. Thompson,et al. Kaposi's sarcoma tumor cells preferentially express Bcl-xL. , 1996, The American journal of pathology.
[176] L. Verburgt,et al. Overexpression of Bcl-2 and mutations in p53 and K-ras in resected human non-small cell lung cancers. , 1996, American journal of respiratory cell and molecular biology.
[177] John Calvin Reed,et al. Elevated expression of Bcl-X and reduced Bak in primary colorectal adenocarcinomas. , 1996, Cancer research.
[178] Z. Werb,et al. Extracellular matrix remodeling and the regulation of epithelial-stromal interactions during differentiation and involution. , 1996, Kidney international. Supplement.
[179] M J Bissell,et al. A hierarchy of ECM-mediated signalling regulates tissue-specific gene expression. , 1995, Current opinion in cell biology.
[180] L. From,et al. bcl-2 protein expression in melanocytic neoplasms of the skin. , 1995, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.
[181] J. Camonis,et al. Self-association of the Death Domains of the p55 Tumor Necrosis Factor (TNF) Receptor and Fas/APO1 Prompts Signaling for TNF and Fas/APO1 Effects (*) , 1995, The Journal of Biological Chemistry.
[182] D. Chopin,et al. Detection of the apoptosis-suppressing oncoprotein bc1-2 in hormone-refractory human prostate cancers. , 1993, The American journal of pathology.
[183] F. Behm,et al. Prolonged survival of B-lineage acute lymphoblastic leukemia cells is accompanied by overexpression of bcl-2 protein. , 1993, Blood.
[184] Y. Tsujimoto,et al. Involvement of the bcl-2 gene in human follicular lymphoma. , 1985, Science.
[185] A. Wyllie,et al. Apoptosis: A Basic Biological Phenomenon with Wide-ranging Implications in Tissue Kinetics , 1972, British Journal of Cancer.
[186] C. Day,et al. Assembling the building blocks: structure and function of inhibitor of apoptosis proteins , 2010, Cell Death and Differentiation.
[187] C. Duckett,et al. XIAP as a ubiquitin ligase in cellular signaling , 2010, Cell Death and Differentiation.
[188] R. Agami,et al. Tumorigenicity of the miR-17-92 cluster distilled. , 2010, Genes & development.
[189] M. Karin,et al. Is NF-κB a good target for cancer therapy? Hopes and pitfalls , 2009, Nature Reviews Drug Discovery.
[190] A. Strasser,et al. The BCL-2 protein family: opposing activities that mediate cell death , 2008, Nature Reviews Molecular Cell Biology.
[191] Juan F. García,et al. Homozygous deletions localize novel tumor suppressor genes in B-cell lymphomas. , 2007, Blood.
[192] Sharad Kumar,et al. Caspase function in programmed cell death , 2007, Cell Death and Differentiation.
[193] A. Venditti,et al. Combined analysis of bcl-2 and MDR1 proteins in 256 cases of acute myeloid leukemia. , 2004, Haematologica.
[194] H. Pehamberger,et al. Small interfering RNA targeting bcl-2 sensitizes malignant melanoma. , 2003, Oligonucleotides.
[195] Wafik S El-Deiry,et al. Defining characteristics of Types I and II apoptotic cells in response to TRAIL. , 2002, Neoplasia.
[196] M J Bissell,et al. The importance of the microenvironment in breast cancer progression: recapitulation of mammary tumorigenesis using a unique human mammary epithelial cell model and a three-dimensional culture assay. , 1996, Biochemistry and cell biology = Biochimie et biologie cellulaire.